170 related articles for article (PubMed ID: 31720832)
1. Assessment of two different HER2 scoring systems and clinical relevance for colorectal cancer.
Liu F; Ren C; Jin Y; Xi S; He C; Wang F; Wang Z; Xu RH; Wang F
Virchows Arch; 2020 Mar; 476(3):391-398. PubMed ID: 31720832
[TBL] [Abstract][Full Text] [Related]
2. Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population.
Ni S; Wang X; Chang J; Sun H; Weng W; Wang X; Tan C; Zhang M; Wang L; Huang Z; Huang D; Xu M; Sheng W
Front Oncol; 2022; 12():842787. PubMed ID: 35574415
[TBL] [Abstract][Full Text] [Related]
3. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
Sartore-Bianchi A; Amatu A; Porcu L; Ghezzi S; Lonardi S; Leone F; Bergamo F; Fenocchio E; Martinelli E; Borelli B; Tosi F; Racca P; Valtorta E; Bonoldi E; Martino C; Vaghi C; Marrapese G; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Torri V; Marsoni S; Siena S
Oncologist; 2019 Oct; 24(10):1395-1402. PubMed ID: 30952821
[TBL] [Abstract][Full Text] [Related]
6. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
[TBL] [Abstract][Full Text] [Related]
7. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
[TBL] [Abstract][Full Text] [Related]
10. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.
Valtorta E; Martino C; Sartore-Bianchi A; Penaullt-Llorca F; Viale G; Risio M; Rugge M; Grigioni W; Bencardino K; Lonardi S; Zagonel V; Leone F; Noe J; Ciardiello F; Pinto C; Labianca R; Mosconi S; Graiff C; Aprile G; Frau B; Garufi C; Loupakis F; Racca P; Tonini G; Lauricella C; Veronese S; Truini M; Siena S; Marsoni S; Gambacorta M
Mod Pathol; 2015 Nov; 28(11):1481-91. PubMed ID: 26449765
[TBL] [Abstract][Full Text] [Related]
11. HER2: An emerging target in colorectal cancer.
Greally M; Kelly CM; Cercek A
Curr Probl Cancer; 2018 Nov; 42(6):560-571. PubMed ID: 30100092
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions.
Moussa M; Badawy A; Helal N; Hegab F; Youssef M; Aboushousha T; Al Faruok L; Elwy D
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2357-2366. PubMed ID: 32856866
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer.
Yagisawa M; Sawada K; Nakamura Y; Fujii S; Yuki S; Komatsu Y; Yoshino T; Sakamoto N; Taniguchi H
Clin Colorectal Cancer; 2021 Jun; 20(2):113-120.e1. PubMed ID: 33384243
[TBL] [Abstract][Full Text] [Related]
14. Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
Shan L; Lv Y; Bai B; Huang X; Zhu H
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2275-2281. PubMed ID: 30203148
[TBL] [Abstract][Full Text] [Related]
15. HER3 protein expression in relation to HER2 positivity in patients with primary colorectal cancer: clinical relevance and prognostic value.
Seo AN; Kwak Y; Kim WH; Kim DW; Kang SB; Choe G; Lee HS
Virchows Arch; 2015 Jun; 466(6):645-54. PubMed ID: 25739551
[TBL] [Abstract][Full Text] [Related]
16. Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.
Gao FJ; Chen JY; Wu HY; Shi J; Chen M; Fan XS; Huang Q
Int J Clin Exp Pathol; 2014; 7(4):1572-9. PubMed ID: 24817953
[TBL] [Abstract][Full Text] [Related]
17. Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.
D'Angelo F; Monnien F; Overs A; Pem I; Dor F; Abad M; Felix S; Selmani Z; Lakkis Z; Borg C; Doussot A; Bibeau F; Molimard C
Diagn Pathol; 2024 Jun; 19(1):88. PubMed ID: 38909265
[TBL] [Abstract][Full Text] [Related]
18. Death decoy receptor overexpression and increased malignancy risk in colorectal cancer.
Zong L; Chen P; Wang DX
World J Gastroenterol; 2014 Apr; 20(15):4440-5. PubMed ID: 24764685
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu testing in primary colorectal carcinoma.
Ingold Heppner B; Behrens HM; Balschun K; Haag J; Krüger S; Becker T; Röcken C
Br J Cancer; 2014 Nov; 111(10):1977-84. PubMed ID: 25211663
[TBL] [Abstract][Full Text] [Related]
20. Does overexpression of HER-2 correlate with clinicopathological characteristics and prognosis in colorectal cancer? Evidence from a meta-analysis.
Wu SW; Ma CC; Li WH
Diagn Pathol; 2015 Aug; 10():144. PubMed ID: 26276145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
